GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Single Ascending Doses Study of Anti- Interleukin-7 Receptor α Monoclonal Antibody (GSK2618960) in Healthy Volunteers

Phase 1

Completed

Conditions: Autoimmune Diseases

Interventions: Drug: Placebo
Drug: GSK2618960

First Posted Date: 2014-11-18

Last Posted Date: 2017-05-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 18

Registration Number: NCT02293161

Locations: 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom

Cross-sectional Study for Identification and Description of Severe Asthma Patients

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Short Acting Beta Agonist (SABA)

First Posted Date: 2014-11-18

Last Posted Date: 2016-04-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 767

Registration Number: NCT02293265

Locations: 🇬🇧
GSK Investigational Site, Trowbridge, United Kingdom

Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies

Phase 3

Completed

Conditions: Obstetric Labour, Premature

Interventions: Drug: Placebo
Drug: Atosiban
Drug: Retosiban

First Posted Date: 2014-11-17

Last Posted Date: 2020-07-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 98

Registration Number: NCT02292784

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Randomized Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban for Women in Spontaneous Preterm Labour

Phase 3

Terminated

Conditions: Obstetric Labour, Premature

Interventions: Drug: Atosiban
Drug: Retosiban
Drug: Placebo matching retosiban
Drug: Placebo matching atosiban

First Posted Date: 2014-11-17

Last Posted Date: 2020-07-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 97

Registration Number: NCT02292771

Locations: 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom

A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors

Phase 1

Withdrawn

Conditions: Cancer

Interventions: Drug: Trametinib 0.5 mg
Drug: Trametinib 2 mg
Drug: ORTHO-NOVUM® tablet 1/35
Drug: Placebo

First Posted Date: 2014-11-17

Last Posted Date: 2016-01-26

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT02292732

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

Phase 1

Terminated

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: GSK2838232
Drug: Placebo
Drug: Ritonavir

First Posted Date: 2014-11-13

Last Posted Date: 2017-05-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 24

Registration Number: NCT02289495

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

Phase 1

Terminated

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: GSK2838232 PIB (SDD)
Drug: Placebo
Drug: GSK2838232 PIB (API)
Drug: Ritonavir

First Posted Date: 2014-11-13

Last Posted Date: 2017-05-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 20

Registration Number: NCT02289482

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study

Completed

Conditions: Meningococcal Disease
Infections, Meningococcal

Interventions: Biological: Meningococcal quadrivalent CRM-197 conjugate vaccine

First Posted Date: 2014-11-11

Last Posted Date: 2019-10-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 144

Registration Number: NCT02287688

Locations: 🇺🇸
GSK Investigational Site, Pasadena, California, United States

Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Phase 2

Completed

Conditions: Meningococcal Disease

Interventions: Biological: Placebo
Biological: Meningococcal ABCWY

First Posted Date: 2014-11-07

Last Posted Date: 2018-09-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 189

Registration Number: NCT02285777

Locations: 🇺🇸
GSK Investigational Site, Cleveland, Ohio, United States

Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Biological: Placebo weekly injection
Biological: Albiglutide weekly injection
Biological: Insulin

First Posted Date: 2014-11-05

Last Posted Date: 2020-06-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 67

Registration Number: NCT02284009

Locations: 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy